Table 5.
Association between intake of antihypertensive and antidiabetic medications and risk of death and progression among epithelial ovarian cancer patients, Ovarian Cancer Association Consortium
| Medications | Dead | Alive | HR (95% CI)a,b | Progression | No progression | HR (95% CI)c |
|---|---|---|---|---|---|---|
| Angiotensin-converting enzyme inhibitor | ||||||
| No | 875 | 558 | 1.00 (ref) | 425 | 270 | 1.00 (ref) |
| Yes | 36 | 31 | 0.87 (0.62–1.23) | 16 | 12 | 1.24 (0.74–2.07) |
| Beta blocker | ||||||
| No | 1,169 | 807 | 1.00 (ref) | 787 | 384 | 1.00 (ref) |
| Yes | 219 | 99 | 1.20 (1.03–1.40) | 161 | 66 | 1.11 (0.93–1.32) |
| Calcium channel blocker | ||||||
| No | 879 | 565 | 1.00 (ref) | 426 | 201 | 1.00 (ref) |
| Yes | 103 | 47 | 0.84 (0.68–1.03) | 64 | 23 | 0.93 (0.70–1.24) |
| Diuretic | ||||||
| No | 905 | 718 | 1.00 (ref) | 424 | 201 | 1.00 (ref) |
| Yes | 52 | 53 | 0.71 (0.53–0.94) | 7 | 2 | 1.14 (0.54–2.42) |
| Any antihypertensive medications | ||||||
| No | 1,108 | 904 | 1.00 (ref) | 731 | 369 | 1.00 (ref) |
| Yes | 415 | 243 | 1.00 (0.89–1.13) | 281 | 109 | 1.10 (0.95–1.28) |
| Oral antidiabetic medications | ||||||
| No | 763 | 719 | 1.00 (ref) | 449 | 208 | 1.00 (ref) |
| Yes | 117 | 86 | 1.28 (1.05–1.55) | 85 | 37 | 0.97 (0.77–1.23) |
| Insulin | ||||||
| No | 1,023 | 915 | 1.00 (ref) | 475 | 221 | 1.00 (ref) |
| Yes | 44 | 19 | 1.63 (1.20–2.20) | 27 | 8 | 1.18 (0.80–1.75) |
Models adjusted for age at diagnosis and stage of disease
Data provided by AUS, NEC, and NJO for ACE inhibitors and calcium channel blockers; AUS, HOP, NEC, and NJO for beta blockers; AUS, NEC, NJO, and NTH for diuretics; AUS, HOP, NEC, NJO, and NTH for all hypertensive medications; HAW, HOP, NEC, NJO, and NTH for oral antidiabetic medications; CON, HAW, HOP, NEC, NJO, and NTH for insulin
Data provided by AUS and NEC for ACE inhibitors, calcium channel blockers, beta blockers, diuretics, all hypertensive medications; HAW and NEC for oral antidiabetic medications and insulin